Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

APPRAISE-1 (10mg od), 2009 - apixaban vs placebo

SEPIA-ACS1 TIMI 42, 2009 - otamixaban vs unfractioned heparin

PLATO, 2009 - ticagrelor + aspirin vs clopidogrel + aspirin

ATLAS ACS-TIMI 46, 2009 - rivaroxaban vs placebo

APPRAISE-1 (2.5 mg bid), 2009 - apixaban vs placebo

DISPERSE-2 (90mg), 2007 - ticagrelor + aspirin vs clopidogrel + aspirin

INTERACT, 2006 - enoxaparin vs UFH (on top of aspirin)

OASIS 5, 2006 - fondaparinux vs enoxaparin

PROTECT-TIMI 30, 2006 - Bivalirudin vs eptifibatide + heparin

SYNERGY, 2005 - enoxaparin vs UFH (on top of aspirin)

EVET, 2005 - enoxaparin vs tinzaparin

LoWASA, 2004 - warfarin vs control (on top of aspirin)

PENTUA, 2004 - fondaparinux vs enoxaparin

Zibaeenezhad, 2004 - warfarin vs control (on top of aspirin)

APRICOT-2, 2002 - warfarin vs control (on top of aspirin)

ASPECT-2 (coumadin+asp vs asp), 2002 - coumadin vs control (on top of aspirin)

WARIS, 2002 - warfarin vs control (on top of aspirin)

ASPECT-2 (coumadin vs aspirin), 2002 - coumadin vs aspirin

CHAMP, 2002 - warfarin vs control (on top of aspirin)

OASIS-2 Warfarin Substudy, 2001 - warfarin vs control (on top of aspirin)

CURE, 2001 - clopidogrel + aspirin vs aspirin

Huyhn, 2001 - warfarin vs placebo (on top of aspirin)

TIM, 2000 - triflusal vs aspirine

HIT-4, 1999 - Hirudin vs heparin

Klootwijk, 1999 - Efegatran vs heparin



See also:

  • All acute coronary syndrome clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of aspirin
    		•  

    VA-pilot study, 0

    unpublished (or not yet fully published) trial

    Treatments

    Studied treatment Aspirin 324 mg/d
    Control treatment

    Patients

    Method and design

    Randomized effectives 26 / 24 (studied vs. control)
    Follow-up duration 3m


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Non fatal MI

    0 / 26
         1 / 24
         classic 0,18 [0,00;13,05]

    Vascular death

    1 / 26
         3 / 24
         classic 0,31 [0,03;2,76]

    Non vascular death

    0 / 26
         0 / 24
         classic 0,92 [0,00;229,49]

    Non fatal stroke

    0 / 26
         0 / 24
         classic 0,92 [0,00;229,49]

    Vascular events

    1 / 26
         4 / 24
         0,23 [0,03;1,92]

    Major bleeding

    0 / 26
         0 / 24
         classic 0,92 [0,00;229,49]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Non fatal MI 0 / 26 (1,9%) 1 / 24 (4,2%) 0,46 [0,02;13,14]    
    Vascular death 1 / 26 (3,8%) 3 / 24 (12,5%) 0,31 [0,03;2,76]    
    Non vascular death 0 / 26 (1,9%) 0 / 24 (2,1%) 0,92 [0,02;44,72]    
    Non fatal stroke 0 / 26 (1,9%) 0 / 24 (2,1%) 0,92 [0,02;44,72]    
    Vascular events 1 / 26 (3,8%) 4 / 24 (16,7%) 0,23 [0,03;1,92]    
    Major bleeding 0 / 26 (1,9%) 0 / 24 (2,1%) 0,92 [0,02;44,72]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Vascular death 3,85% 12,50% -86,5‰
    Vascular events 3,85% 16,67% -128,2‰


    Reference(s)

    unpublished (or not yet fully published) trial

    Trials register # NA

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend